Cell Biology Unit, University Medical Center Mainz, JGU-Mainz, Mainz, Germany.
Department of Dermatology, University Medical Center Mainz, JGU-Mainz, Mainz, Germany.
Cell Death Differ. 2020 Apr;27(4):1300-1315. doi: 10.1038/s41418-019-0416-4. Epub 2019 Sep 20.
RAF kinases (ARAF, BRAF, and CRAF) are highly conserved enzymes that trigger the RAF-MEK1/2-ERK1/2 (MAPK) pathway upon activation of RAS. Despite enormous clinical interest, relatively little is known on the role of RAFs in mediating immune responses. Here, we investigated the role of RAF kinases and MEK1/2 in dendritic cells (DCs), the central regulators of T cell-mediated antitumor immune responses and the adaptive immune system. We demonstrate that RAF kinases are active and stabilized at their protein levels during DC differentiation. Inhibition of RAF kinases but not MEK1/2 impaired the activation of DCs in both mice and human. As expected, DCs treated with RAF inhibitors show defects in activating T cells. Further, RAF and MEK1/2 kinases are directly required for the activation and proliferation of CD4 T cells. Our observations suggest that RAF and MEK1/2 have independent roles in regulating DC function that has important implications for administering RAF-MAPK inhibitors in the clinics.
RAF 激酶(ARAF、BRAF 和 CRAF)是高度保守的酶,在 RAS 激活后触发 RAF-MEK1/2-ERK1/2(MAPK)通路。尽管具有巨大的临床兴趣,但 RAF 在介导免疫反应中的作用相对知之甚少。在这里,我们研究了 RAF 激酶和 MEK1/2 在树突状细胞(DC)中的作用,DC 是 T 细胞介导的抗肿瘤免疫反应和适应性免疫系统的中枢调节剂。我们证明 RAF 激酶在 DC 分化过程中在其蛋白质水平上是活跃和稳定的。RAF 激酶的抑制而不是 MEK1/2 的抑制损害了小鼠和人类 DC 的激活。正如预期的那样,用 RAF 抑制剂处理的 DC 在激活 T 细胞方面存在缺陷。此外,RAF 和 MEK1/2 激酶直接参与 CD4 T 细胞的激活和增殖。我们的观察表明,RAF 和 MEK1/2 在调节 DC 功能方面具有独立的作用,这对在临床上施用 RAF-MAPK 抑制剂具有重要意义。